Autoimmune gastritis (AIG) has been traditionally recognised as a precursor to type I gastric neuroendocrine tumours and ...
Background The optimal timing of endoscopic retrograde cholangiopancreatography (ERCP) in patients with mild-to-moderate acute cholangitis remains uncertain. Objective To compare the clinical outcomes ...
6 Research School of Biology, Australian National University, Canberra, Australian Capital Territory, Australia Correspondence to Dr Claire O'Brien, Medical School, Australian National University, ...
4 Department of Hepatogastroenterology, Hopital Claude Huriez, CHRU Lille, France Correspondence to: Professor J-F Colombel Department of Hepato-Gastroenterology, Hopital Claude Huriez, CHRU de Lille, ...
Gut microbiome signatures in colorectal neoplasia: a cross-sectional study across neoplasia stages and subtypes ...
Objective The benefits of pancreatic enzyme replacement therapy (PERT) in chronic pancreatitis (CP) are inadequately defined. We have undertaken a systematic review and meta-analysis of randomised ...
Background and aims A general dysbiosis of the intestinal microbiota has been established in patients with Crohn's disease (CD), but a systematic characterisation of this dysbiosis is lacking.
Background: The colonic epithelium maintains a life long reciprocally beneficial interaction with the colonic microbiota. Disruption is associated with mucosal injury. Aims: We hypothesised that ...
Correspondence to Dr Silvio Danese, Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Lombardia, Italy; ...
a INSERM U45, Hôpital Edouard Herriot, Lyon, France, b Laboratoire d'Ecologie et de Physiologie du Système Digestif, INRA, Centre de Recherche de Jouy-en-Josas, France Dr P Plaisancié, INSERM U-45, ...
Introduction Post colonoscopy colorectal cancers (PCCRC) are diagnosed within 5 years of an index colonoscopy without a colorectal cancer (CRC) diagnosis and post endoscopy upper gastrointestinal ...
Correspondence to Dr Massimiliano di Pietro, MRC Cancer Unit, University of Cambridge, Cambridge Biomedical Campus, P.O. Box 197, Cambridge CB2 0XZ, UK; md460{at}mrc-cu.cam.ac.uk The most recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results